Loss of MTAP expression is a negative prognostic marker in Ewing sarcoma family of tumors-Reference-Cited by-同舟云学术

Loss of MTAP expression is a negative prognostic marker in Ewing sarcoma family of tumors

Published:2018-01 Issue:1 Volume:12 Page:35-44
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Abrahao-Machado Lucas Faria¹,Antunes Bruno²,Filippi Renee Zon³,Volc Sahlua⁴,Boldrini Erica⁵,Menezes Weder P⁶,Reis Rui M⁶⁷⁸,de Camargo Olavo Pires³

Affiliation:

1. Department of Pathology & Molecular Diagnosis, Barretos Cancer Hospital, Barretos, SP, Brazil

2. Department of Othopedics Surgery, Barretos Cancer Hospital, Barretos, SP, Brazil

3. Institute of Orthopedics & Traumatology, Faculty of Medicine, University of São Paulo (FMUSP), São Paulo, SP, Brazil

4. Oncology Department, Barretos Cancer Hospital, Barretos, SP, Brazil

5. Pediatrics Department, Barretos Cancer Hospital, Barretos, SP, Brazil

6. Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil

7. Life & Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal

8. ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal

Abstract

Aim: The Ewing sarcoma family of tumors (ESFT) is a group of malignant small round cell neoplasms of bones and soft tissues closely histogenetically related. Methylthioadenosine phosphorylase (MTAP) deficiency has been recently associated with increased tumor aggressiveness and poor outcomes in different types of neoplasms. However, the expression of this biomarker and its biological role in ESFT remain largely unknown. Methods: Immunohistochemical expression of MTAP was accessed in 112 patients with ESFT in a tissue microarray platform and associated with clinicopathological parameters and overall survival (OS). Results: Loss of MTAP expression was significantly associated with lower OS in both univariate and multivariate analyses. Conclusion: Loss of MTAP expression is an independent negative prognostic biomarker in ESFT.

Publisher

Future Medicine Ltd

Subject

Biochemistry, medical,Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2017-0152

Reference20 articles.

1. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity

2. Selective Killing of Tumors Deficient in Methylthioadenosine Phosphorylase: A Novel Strategy

3. MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients

4. Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines

5. Expression of Methylthioadenosine Phosphorylase (MTAP) in Pilocytic Astrocytomas

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of S-methyl-5′-thioadenosine Phosphorylase (MTAP) Deficiency in Human Cancer;American Journal of Surgical Pathology;2024-08-12

3. Molecular and biologic biomarkers of Ewing sarcoma: A systematic review;Journal of Bone Oncology;2023-06

4. Clinical impact of brachyury expression in Ewing sarcoma patients;Advances in Medical Sciences;2021-09

5. MTAP Deficiency–Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer;Cancer Research;2021-08-12